Kenneth L. van Golen
Kenneth L. van Golen
Office: 320 Wolf Hall
Lab: Helen F Graham Christiana Care Research Institute
Resources and Links
Education
- B.S. - Michigan State University
- Ph.D. - University of Texas, Health Science Center
- Postdoctoral - University of Michigan
Teaching
- BISC612 - Advanced Cell Biology
- BISC605/606 - Advanced Human Physiology
- BISC400 - Special Topics: Signal Transduction
Research Interests
Since 1996 my research has been focused on understanding the biology of a unique and aggressive form of breast cancer known as Inflammatory Breast Cancer (IBC). IBC accounts for approximately 5% of breast cancers annually but is responsible for 10% of breast cancer deaths in the U.S.A. IBC is a "lumpless" breast cancer and is hallmarked by distinct changes in the appearance of the breast, particularly the skin, resembling an infection. This disease typically affects younger women and has been reported in girls as young as 12 years old. IBC has a 42% and 18% 5- and 10-year-disease-free survival rate, respectively. In comparison to non-inflammatory breast cancers which have 90% and 83% 5- and 10-year-disease-free survival rates.
Current Projects
The role of the platelet derived growth factor receptor alpha in inflammatory breast cancer progression- Our previous research has demonstrated a significant increase in expression of the platelet derived growth factor receptor alpha (PDGFRA) in IBC versus non-IBC tumors. We also demonstrated that the level of expression of PDGFRA is predictive of patient survival. Currently, we are determining how this receptor affects IBC tumor cell growth and survival. We are also working on repurposing a drug currently in the clinic for gastrointestinal stromal tumors to as a therapy for IBC.